JPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN)

JPMorgan Chase & Co. trimmed its position in Compugen Ltd. (NASDAQ:CGEN) by 62.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,485 shares of the biotechnology company’s stock after selling 113,287 shares during the quarter. JPMorgan Chase & Co. owned about 0.08% of Compugen worth $122,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Compugen by 82.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 124,190 shares during the period. Atom Investors LP lifted its stake in Compugen by 27.5% during the third quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 32,701 shares during the period. Joel Isaacson & Co. LLC boosted its holdings in Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 30,000 shares in the last quarter. Squarepoint Ops LLC raised its stake in Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 16,253 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 8,350 shares in the last quarter. 12.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Oppenheimer assumed coverage on Compugen in a research report on Monday, January 13th. They issued an “outperform” rating and a $4.00 price objective for the company.

Compugen Stock Down 0.9 %

Shares of CGEN stock opened at $2.33 on Monday. Compugen Ltd. has a 12 month low of $1.35 and a 12 month high of $3.03. The firm has a market cap of $207.93 million, a price-to-earnings ratio of 116.50 and a beta of 2.59. The stock has a 50-day moving average price of $1.78 and a 200 day moving average price of $1.77.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.20). Compugen had a net margin of 2.67% and a return on equity of 2.62%. The business had revenue of $17.13 million during the quarter, compared to analyst estimates of $17.67 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. Sell-side analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.